-
Mashup Score: 0Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes. - 10 hour(s) ago
Following a recent update in to NCCN gGuidelines, Drs. Garcia- Manero and Swoboda introduce themselves and theirwill discussion about the changing landscape of lower-risk myelodysplastic syndromeLR-MDS treatment.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Study Suggests ESAs Have High Rates of Failure in Lower-Risk MDS | Blood Cancers Today - 6 day(s) ago
ESAs had a high rate of failure among patients with lower-risk MDS and often continued treatment despite failure.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
ESAs had a high rate of failure overall and across key subgroups based on ring sideroblast status and erythropoietin level among patients with lower-risk #MDS, according to an analysis from the Florida Cancer Specialists & Research Institute. ➡️ https://t.co/imUqWYkhz3 https://t.co/jjj35VkxEe
-
-
Mashup Score: 1
Tapotoclax was safe and may warrant consideration in combination with other therapies in MDS post-HMA failure.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
☑️ Tapotoclax is safe in patients with #MDS after hypomethylating agent failure, according to a study led by Kelly Chien, MD, of @MDAndersonNews. 📰 Read more: https://t.co/OXIjXbOUQa https://t.co/3wC1WC3krw
-
-
Mashup Score: 2Dr Garcia-Manero on the Impact of Luspatercept on Hematopoietic Lineages in Lower-Risk MDS - 7 day(s) ago
Guillermo Garcia-Manero, MD, discusses the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk MDS.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Hear @garciamanero of @MDAndersonNews discuss the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk #MDS. https://t.co/xhHu8s5DSD https://t.co/RnQL79ITyq
-
-
Mashup Score: 5
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
💬 A roundtable discussion with Drs. Guillermo Garcia-Manero (@MDAndersonNews), Jamie Koprivnikar (@HMHNewJersey), Solly Chedid (@mySingingRiver), and @tomleblancMD (@DukeCancer) discussed imetelstat for lower-risk #MDS. ➡️ Check it out! https://t.co/F9JnsvOue0 https://t.co/1Vod1Nyu40
-
-
Mashup Score: 3
Bertrand Y. Tuan, MD, discusses the therapies relevant to patients with low-risk myelodysplastic syndrome.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Bertrand Y. Tuan, MD, discusses the therapies relevant to patients with low-risk myelodysplastic syndrome. #MDS https://t.co/jarmf1S4gq
-
-
Mashup Score: 1Jamie Koprivnikar, MD, Talks COMMANDS Trial, Luspatercept Dosing | Blood Cancers Today - 20 day(s) ago
More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🗨️ Jamie Koprivnikar, MD, of @HMHNewJersey @JTCancerCenter, discusses her thoughts on the COMMANDS trial of luspatercept versus epoetin alfa in patients with #MDS! 📺 Watch here: https://t.co/52baQtJDkN https://t.co/Z3RMrddikh
-
-
Mashup Score: 2Myelodysplastic Syndromes | Blood Cancers Today - 23 day(s) ago
Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. Read the latest news.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
What's new in #MDS? @kristenpettitmd, of @umichmedicine, recently highlighted some recent research for our knowledge hub. Check it out below! ⬇️⬇️⬇️ https://t.co/p2M1CNkdZT https://t.co/Z2cfCOZBd4
-
-
Mashup Score: 0New Human Bone Marrow Organoid Model Helps Optimize MDS Therapy Research | Blood Cancers Today - 24 day(s) ago
The model’s superior engrafting of HSPCs from patients with MDS brings better replication of the disease microenvironment.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🙌 @Kehan_Ren_PhD, @PengJi_lab, and other researchers from @NorthwesternU have developed a new human bone marrow organoid model to help optimize #MDS therapy research. 📰 Read more: https://t.co/rqnGdUUvj7 https://t.co/Y8ufAa1kXc
-
-
Mashup Score: 3
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
❓ Can electronic medical record alerts help optimize luspatercept dosing in #MDS? 💡 Learn more from this roundtable discussion with Jamile Shammo, @MdSwoboda, Saeed Sadeghi, and @benton_leukemia. ➡️ https://t.co/86oV2u7viD https://t.co/esEivn3g67
-
Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes. #MDS @MdSwoboda https://t.co/uJKNbRAtHT